title: [Effect of shenqi fuzheng injection for assistance of chemotherapy in treating senile patients with non-small cell lung cancer].
abstract: OBJECTIVE
  To study the effect of chemotherapy assisted with shenqi fuzheng injection (SFI) on senile patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  One hundred and twenty old patients with NSCLC were treated with NP chemotherapeutic protocol, to the 60 patients in the treated group among them, additional medication of SFI was started one week before the beginning of chemotherapy. The short-term therapeutic efficacy, long-term survival rate, changes on quality of life (QOL) and immune function of patients, and hematological toxicity of therapy were observed.
  
  
  RESULTS
  Difference between the two groups on short-term therapeutic effect, 1- and 2-year survival rate showed no significance (P>0.05), but the 3-year survival rate in the treated group was 26.6%, while that in the control group was 11.7%, showed that the former was higher than the latter. After treatment QOL of the treated group was better than that of the control (P<0.05). Besides, the hematological toxicity and affection on immune function of chemotherapy after treatment in the treated group were all lower than those in the control group showing significant difference (P<0.05).
  
  
  CONCLUSIONS
  SFI has definite toxicity relieving effect on chemotherapy in treating senile NSCLC.
authors.affiliation: Guangzhou Municipal Tumor Hospital, Clinical Research Center of Tumor, Guangzhou Medical College, Guangzhou 510095. liuguanghong@hotmail.com
authors.forename: Cheng-lin
authors.initials: CL
authors.lastname: Liu
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Chen
authors.forename: Shu-zhong
authors.initials: SZ
authors.lastname: Cui
authors.forename: Guangye
authors.initials: G
authors.lastname: Deng
authors.forename: Liping
authors.initials: L
authors.lastname: Liu
authors.forename: Lihong
authors.initials: L
authors.lastname: Qin
authors.forename: Xuchun
authors.initials: X
authors.lastname: Su
authors.forename: Bingchuan
authors.initials: B
authors.lastname: Yan
authors.forename: Jiaxin
authors.initials: J
authors.lastname: Kong
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000276:immunology; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D011788:Quality of Life
chemical_list: D004365:Drugs, Chinese Herbal